Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 ...

The beautiful yet dangerous Portuguese-men-of-war is filled with air allowing it to float on top of the water and travel with ...

The pharmaceutical company's two main products, Syfovre and Empaveli, did not meet sales projections. Syfovre generated $152 million, falling short by $15.7 million, while Empaveli brought in $24.6 ...

The firm thinks Q3 was validating for its view of a slowing GA market and that Syfovre estimates need to be reset. Wells believes incrementally negative commentary on pricing and more gradual ramp ...

Archaeologists first made the grim discovery in 2022 and have been studying the remains to understand why she and others were ...

In connection with the Empaveli/Syfovre Transaction completed in 2022, the Trust acquired other current assets. The related amortization expense is recorded in other operating expenses.

Nov. 8, 2024 — Tool use isn't unique to humans. Chimpanzees use sticks as tools. Dolphins, crows, and elephants are known for their tool-use abilities, too. Now a report highlights elephants ...

We may earn an affiliate commission from links. Over the past few years, and thanks in no small part to TikTok, face yoga has become one of the most discussed above-the-neck sculpting techniques.

That approval set up a market clash with Apellis Pharma's complement C3 inhibitor Syfovre (pegcetacoplan), which was cleared a few months earlier. There are currently no approved treatments ...